Cyclosporine
Brand names: Cyclosporine, Restasis, Restasis Multidose, Verkazia, Cequa, Sandimmune, Vevye
At a glance
- Medicare prescriptions, 2024
- 1,832,618
- Medicare drug cost
- $1.42B
- Average cost per prescription
- $776
- Clinicians who prescribed it
- 28,553
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
1 IN DICATIONS AND USAGE RESTASIS ® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
From the FDA-approved prescribing information (label dated September 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Ophthalmology 54.2%
- Optometrists 34.3%
- Internal Medicine 4.3%
- Family Medicine 2.6%
- Nurse Practitioners 1.5%
- Retina Specialist 0.9%
- Physician Assistants 0.6%
- Geriatric Medicine 0.5%
- General Practice 0.3%
- Rheumatology 0.1%
- Nephrology (Kidney) 0.1%
- Cardiology 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 30% from 2019 to 2024.
Biggest change by state since 2019
- New Mexico +68%
- Washington +62%
- Louisiana +61%
- Oregon +58%
- Utah +57%
- Hawaii (smallest change) −7%
- Nebraska (smallest change) −3%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | blue oval capsule, 13 mm | S 25 |
| 50 mg | white oval capsule, 19 mm | S 50 |
| 100 mg | gray oval capsule, 25 mm | S 100 |
Qilu Pharmaceutical Co., Ltd.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white oval capsule, 14 mm | 87 |
| 100 mg | white capsule, 28 mm | 88 |
Santen Incorporated
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | white emulsion | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $3.0M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Sun Pharmaceutical Industries Inc. $2.0M
- Harrow Eye, LLC $1.0M
- AbbVie Inc. $32
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
5 recalls since 2020
- Sep 2023 · Sun Pharmaceutical Industries Inc · Class III
Subpotent: Out of Specification result observed for low assay - Sep 2022 · Novartis Pharmaceuticals Corporation · Class II
CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content. - Mar 2022 · Sun Pharmaceutical Industries Inc · Class III
Subpotent Drug and Presence of Particulate Matter: low out-of-specification results obtained for assay and the presence of particulate matter. - May 2021 · Sun Pharmaceutical Industries Inc · Class III
Subpotent and Presence of Particulates. - Feb 2021 · Sun Pharmaceutical Industries Inc · Class III
Subpotent
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.